Jubilant Pharmova Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Strong revenue growth from ₹1,586.90 Crore to ₹1,680.30 Crore in Q2 2023, indicating increased market demand.
Operating profit margin improved significantly, reflecting better cost management and operational efficiencies.
Net profit rebounded to ₹62.10 Crore in Q2 2023, a sharp recovery from previous losses.

NEGATIVES

Profit before tax showed volatility, dropping to -₹61.80 Crore in Q1 2024, suggesting inconsistent performance.
High depreciation costs remain a concern, impacting overall profitability despite rising revenues.
Tax rates fluctuated significantly, affecting net profit predictability and financial planning.

Field	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue	1,680.30	1,677.10	1,758.60	1,731.70	1,752.30	1,821.70	1,928.80	1,900.70
Expenses	1,601.20	1,625	1,661.20	1,641.90	1,615.30	1,681.20	1,731.30	1,758.20
Operating Profit	79.10	52.10	97.40	89.80	137	140.50	197.50	142.50
Other Income	9.90	35.80	14.40	14	21.70	9.20	11.90	12
Interest	66.10	71.30	73	71	61	55.60	52.70	49
Depreciation	96.60	94.60	101	90.70	91.40	91.30	95.20	98.10
Profit Before Tax	98	101	-53.70	499.70	144.40	130.50	206	154.40
Tax	35.90	34.60	8.10	17.90	41.90	29.80	54.70	51.90
Net Profit	62.10	66.40	-61.80	481.80	102.50	100.70	151.30	102.50
Eps in Rs	3.94	4.22	-3.69	30.44	6.47	6.37	9.71	6.49